The TGTX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TGTX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The TGTX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View TGTX Detailed Price Forecast - CNN Money||View TGTX Detailed Summary - Google Finance|
|View TGTX Detailed Summary - Yahoo! Finance||View TGTX Stock Research & Analysis - Zacks.com|
|View TGTX Trends & Analysis - Trade-Ideas||View TGTX Major Holders - Barrons|
|View TGTX Call Transcripts - NASDAQ||View TGTX Breaking News & Analysis - Seeking Alpha|
|View TGTX Annual Report - CompanySpotlight.com||View TGTX OTC Short Report - OTCShortReport.com|
|View TGTX Fundamentals - TradeKing||View TGTX SEC Filings - Bar Chart|
|View Historical Prices for TGTX - The WSJ||View Performance/Total Return for TGTX - Morningstar|
|View the Analyst Estimates for TGTX - MarketWatch||View the Earnings History for TGTX - CNBC|
|View the TGTX Earnings - StockMarketWatch||View TGTX Buy or Sell Recommendations - MacroAxis|
|View the TGTX Bullish Patterns - American Bulls||View TGTX Short Pain Metrics - ShortPainBot.com|
|View TGTX Stock Mentions - StockTwits||View TGTX Stock Mentions - PennyStockTweets|
|View TGTX Stock Mentions - Twitter||View TGTX Investment Forum News - Investor Hub|
|View TGTX Stock Mentions - Yahoo! Message Board||View TGTX Stock Mentions - Seeking Alpha|
|View Insider Transactions for TGTX - SECform4.com||View Insider Transactions for TGTX - Insider Cow|
|View TGTX Major Holdings Summary - CNBC||View Insider Disclosure for TGTX - OTC Markets|
|View Insider Transactions for TGTX - Yahoo! Finance||View Institutional Holdings for TGTX - NASDAQ|
|View TGTX Stock Insight & Charts - FinViz.com||View TGTX Investment Charts - StockCharts.com|
|View TGTX Stock Overview & Charts - BarChart||View TGTX User Generated Charts - Trading View|
TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 71st Annual Meeting
Posted on Tuesday March 12, 2019
TG Therapeutics, Inc. (TGTX), today announced that data from the Phase 2 multicenter trial evaluating ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS) has been selected for presentation at the upcoming American Academy of Neurology (AAN) annual meeting, to be held May 4 – 10, 2019 in Philadelphia, Pennsylvania. Final data from the core Phase 2 trial has been previously presented, most recently at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual meeting in Dallas, TX. In addition to highlighting the final Phase 2 data, the AAN presentation plans to include data from the open label extension (OLE), a trial made available to any patient who completed the core Phase 2 trial allowing them to continue treatment with ublituximab.
What Makes TG Therapeutics (TGTX) a New Strong Buy Stock
Posted on Monday March 11, 2019
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TG Therapeutics to Present at the Cowen 39th Annual Health Care Conference
Posted on Monday March 11, 2019
NEW YORK, March 11, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials
Posted on Friday March 08, 2019
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated cancers and autoimmune diseases, today announced the successful outcome of meetings held by the independent Data Safety Monitoring Boards (DSMBs) for both the UNITY-CLL trial and for the UNITY-NHL trial. Michael S. Weiss, Executive Chairman and Chief Executive Officer of TG Therapeutics stated, "We are highly encouraged that based on the progression-free survival data accumulated to date, the UNITY-CLL DSMB determined that the study was not futile and supported continuation of the trial as planned.